E-therapeutics Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ETXPF research report →
Companywww.etherapeutics.co.uk
e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.
- CEO
- Ahmad Ali Mortazavi
- IPO
- 2020
- Employees
- 39
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $75.96M
- P/E
- -4.71
- P/S
- 177.32
- P/B
- 2.39
- EV/EBITDA
- -2.65
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -4337.74%
- Net Margin
- -3511.32%
- ROE
- -40.58%
- ROIC
- -51.86%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-14,869,000 · -33.16%
- EPS
- $-0.02 · -5.24%
- Op Income
- $-18,646,000
- FCF YoY
- -52.27%
Performance & Tape
- 52W High
- $0.13
- 52W Low
- $0.13
- 50D MA
- $0.13
- 200D MA
- $0.13
- Beta
- 0.42
- Avg Volume
- 0
Get TickerSpark's AI analysis on ETXPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ETXPF Coverage
We haven't published any research on ETXPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ETXPF Report →